1. Stanley TH. The fentanyl story. J Pain 2014;15:1215-26. [DOI:10.1016/j.jpain.2014.08.010]

2. Comer SD, Cahill CM. Fentanyl: Receptor pharmacology, abuse potential, and implications for treatment. Neurosci Biobehav Rev 2019;106:49-57. [DOI:10.1016/j.neubiorev.2018.12.005]

3. Karunarathna I. Fentanyl: clinical applications and pharmacological considerations. Uva Clinical Lab. Retrieved from Fentanyl: clinical applications and pharmacological considerations, 2024. Available from: https://www.researchga te.net/profle/Indunil-Karunarathna/publication/380270478_Fentanyl_ Clinical_Applications_and_Pharmacological_Considerations/links/66338 08d7091b94e93ea9108/Fentanyl-Clinical-Applications-and-Pharmacolo gical-Considerations.pdf.

4. Substance Abuse and Mental Health Services Administration (SAMHSA). Key substance use and mental health indicators in the United States: results from the 2019 National Survey on Drug Use and Health. 2020. Available from: https://www.samhsa.gov/data/sites/default/files/reports/rpt29393/2019NSDUHFFRPDFWHTML/2019NSDUHFFR1PDFW090120.pdf

5. Han Y, Cao L, Yuan K, Shi J, Yan W, Lu L. Unique pharmacology, brain dysfunction, and therapeutic advancements for fentanyl misuse and abuse. Neurosci Bull 2022;38:1365-8. [DOI:10.1007/s12264-022-00872-3]

6. Gold MS, Melker RJ, Dennis DM, Morey TE, Bajpai LK, Pomm R, et al. Fentanyl abuse and dependence: further evidence for second hand exposure hypothesis. J Addict Dis 2006;25:15-21 [DOI:10.1300/J069v25n01_04]

7. Towers EB, Setaro B, Lynch WJ. Sex-and dose-dependent differences in the development of an addiction-like phenotype following extended-access fentanyl self-administration. Front Pharmacol 2022;13:841873. [DOI:10.3389/fphar.2022.841873]

8. Kuczyńska K, Grzonkowski P, Kacprzak Ł, Zawilska JB. Abuse of fentanyl: An emerging problem to face. Forensic Sci Int 2018;289:207-14. [DOI:10.1016/j.forsciint.2018.05.042]

9. Rueda-Ruzafa L, Cruz F, Cardona D, Hone AJ, Molina-Torres G, Sánchez-Labraca N, et al. Opioid system influences gut-brain axis: dysbiosis and related alterations. Pharmacol Res 2020;159:104928. [DOI:10.1016/j.phrs.2020.104928]

10. Che T, Roth BL. Molecular basis of opioid receptor signaling. Cell 2023;186:5203-19. [DOI:10.1016/j.cell.2023.10.029]

11. García-Domínguez M. Enkephalins and pain modulation: mechanisms of action and therapeutic perspectives. Biomolecules 2024;14:926. [DOI:10.3390/biom14080926]

12. Jalodia R, Abu YF, Oppenheimer MR, Herlihy B, Meng J, Chupikova I, et al. Opioid use, gut dysbiosis, inflammation, and the nervous system. J Neuroimmune Pharmacol 2022:1-18. [DOI:10.1007/s11481-021-10046-z]

13. Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Reddy DN. Role of the normal gut microbiota. World journal of gastroenterology: World J Gastroenterol 2015;21:8787-803. [DOI:10.3748/wjg.v21.i29.8787]

14. McCallum G, Tropini C. The gut microbiota and its biogeography. Nat Rev Microbiol 2024;22:105-18. [DOI:10.1038/s41579-023-00969-0]

15. Muchhala KH, Kallurkar PS, Kang M, Koseli E, Poklis JL, Xu Q, et al. The role of morphine‐and fentanyl‐induced impairment of intestinal epithelial antibacterial activity in dysbiosis and its impact on the microbiota‐gut‐brain axis. FASEB J 2024;38:e23603. [DOI:10.1096/fj.202301590RR]

16. Wang F, Meng J, Zhang L, Johnson T, Chen C, Roy S. Morphine induces changes in the gut microbiome and metabolome in a morphine dependence model. Sci Rep 2018;8:3596. [DOI:10.1038/s41598-018-21915-8]

17. Szigethy E, Knisely M, Drossman D. Opioid misuse in gastroenterology and non-opioid management of abdominal pain. Nat Rev Gastroenterol Hepatol 2018;15:168-80. [DOI:10.1038/nrgastro.2017.141]

18. Tavares ALdF, Reginato A, Neves M, Pradal LdA, Leal TSdS, Ribeiro LdFC, et al. Analysis of wistar rats submitted to a gout model, treated with double cryotherapy protocol. Ther Hypothermia Temp Manag 2022;12:30-7. [DOI:10.1089/ther.2021.0001]

19. Rêgo DdSB, Silva CS, Mello LEA, Leslie ATFS. Early life nociceptive stimulus and fentanyl exposure increase hippocampal neurogenesis and anxiety but do not affect spatial learning and memory. Front Neurosci 2022;16:988096. [DOI:10.3389/fnins.2022.988096]

20. Jones J, Reinke SN, Ali A, Palmer DJ, Christophersen CT. Fecal sample collection methods and time of day impact microbiome composition and short chain fatty acid concentrations. Sci Rep 2021;11:13964. [DOI:10.1038/s41598-021-93031-z]

21. Karakaş EU, Pektaş AN, Şeyda B. Selection and Validation of Potential Reference Genes for Quantitative Real-Time PCR Analysis in Blaptica Dubia (Serville, 1838)(Blattidae, Blaberidae). Cumhuriyet Science Journal 2022; 43: 176-82. [DOI:10.17776/csj.1069230]

22. Sayed IM, Inouye K, Das S, Alexander LC. Isolation of RNA from the Murine Colonic Tissue and qRT-PCR for Inflammatory Cytokines. Bio Protoc 2023;13:e4634. [DOI:10.21769/BioProtoc.4634]

23. Xie B, Wang Y, Lu Y, Wang M, Hui R, Yu H, et al. A novel intervention of molecular hydrogen on the unbalance of the gut microbiome in opioid addiction: Experimental and human studies. Biomed Pharmacother 2024;178:117273. [DOI:10.1016/j.biopha.2024.117273]

24. He Q, Zhang Y, Ma Y, Deng X, Zhang H, Zhang Y, et al. Lactobacillus Rhamnosus Reshapes Gut Microbes and Modulates L-kynurenine Metabolism to Decrease Susceptibility to Heroin Addiction in Mice. Research Square [Preprint] 2024. [DOI:10.21203/rs.3.rs-4142387/v1]

25. Wang H, Luo J, Chen X, Hu H, Li S, Zhang Y, et al. Clinical observation of the effects of oral opioid on inflammatory cytokines and gut microbiota in patients with moderate to severe cancer pain: a Retrospective Cohort Study. Pain Ther 2022;11:667-81. [DOI:10.1007/s40122-022-00386-w]

26. Al Bander Z, Nitert MD, Mousa A, Naderpoor N. The gut microbiota and inflammation: an overview. Int J Environ Res Public Health 2020;17:7618. [DOI:10.3390/ijerph17207618]

27. Thomas KR, Watt J, Wu CMJ, Akinrinoye A, Amjad S, Colvin L, et al. Pain and opioid-induced gut microbial dysbiosis. Biomedicines 2022;10:1815. [DOI:10.3390/biomedicines10081815]

28. Mohebali N, Weigel M, Hain T, Sütel M, Bull J, Kreikemeyer B, et al. Faecalibacterium prausnitzii, Bacteroides faecis and Roseburia intestinalis attenuate clinical symptoms of experimental colitis by regulating Treg/Th17 cell balance and intestinal barrier integrity. Biomed Pharmacother 2023;167:115568. [DOI:10.1016/j.biopha.2023.115568]

29. Cervantes-Barragan L, Chai JN, Tianero MD, Di Luccia B, Ahern PP, Merriman J, et al. Lactobacillus reuteri induces gut intraepithelial CD4+ CD8αα+ T cells. Science 2017;357:806-10. [DOI:10.1126/science.aah5825]

30. Jhun J, Cho K-H, Lee D-H, Kwon JY, Woo JS, Kim J, et al. Oral administration of Lactobacillus rhamnosus ameliorates the progression of osteoarthritis by inhibiting joint pain and inflammation. Cells 2021;10:1057. [DOI:10.3390/cells10051057]

31. Liu H, Wang J, He T, Becker S, Zhang G, Li D, et al. Butyrate: a double-edged sword for health? Adv Nutr 2018;9:21-9. [DOI:10.1093/advances/nmx009]

32. Leylabadlo HE, Ghotaslou R, Feizabadi MM, Farajnia S, Moaddab SY, Ganbarov K, et al. The critical role of Faecalibacterium prausnitzii in human health: An overview. Microb Pathog 2020;149:104344. [DOI:10.1016/j.micpath.2020.104344]

33. Oh NS, Joung JY, Lee JY, Kim Y. Probiotic and anti-inflammatory potential of Lactobacillus rhamnosus 4B15 and Lactobacillus gasseri 4M13 isolated from infant feces. PloS One 2018;13:e0192021. [DOI:10.1371/journal.pone.0192021]

34. Hu W, Gao W, Liu Z, Fang Z, Wang H, Zhao J, et al. Specific strains of faecalibacterium prausnitzii ameliorate nonalcoholic fatty liver disease in mice in association with gut microbiota regulation. Nutrients 2022;14:2945. [DOI:10.3390/nu14142945]

35. Ma Y, Sannino D, Linden JR, Haigh S, Zhao B, Grigg JB, et al. Epsilon toxin-producing Clostridium perfringens colonize the multiple sclerosis gut microbiome overcoming CNS immune privilege. J Clin Invest 2023;133: e163239. [DOI:10.1172/JCI163239]

36. Cao W, Zheng C, Xu X, Jin R, Huang F, Shi M, et al. Clostridium butyricum potentially improves inflammation and immunity through alteration of the microbiota and metabolism of gastric cancer patients after gastrectomy. Front Immunol 2022;13:1076245. [DOI:10.3389/fimmu.2022.1076245]

37. Zádori ZS, Király K, Al-Khrasani M, Gyires K. Interactions between NSAIDs, opioids and the gut microbiota-future perspectives in the management of inflammation and pain. Pharmacol Ther 2023;241:108327. [DOI:10.1016/j.pharmthera.2022.108327]

38. Lee C-G, Hwang S, Gwon S-Y, Park C, Jo M, Hong J-E, et al. Bacteroides fragilis toxin induces intestinal epithelial cell secretion of interleukin-8 by the e-Cadherin/β-Catenin/NF-κB dependent pathway. Biomedicines 2022;10:827. [DOI:10.3390/biomedicines10040827]

39. Boyko N, Costigliola V, Golubnitschaja O. Microbiome in the Framework of Predictive, Preventive and Personalised Medicine. In: Boyko N, Golubnitschaja O, eds. Microbiome in 3P Medicine Strategies. Advances in Predictive, Preventive and Personalised Medicine. Berline: Springer; 2023. p.1-8. [DOI:10.1007/978-3-031-19564-8_1]

40. Ren M, Lotfipour S. The role of the gut microbiome in opioid use. Behav Pharmacol 2020;31:113-21. [DOI:10.1097/FBP.0000000000000538]